Zobrazeno 1 - 10
of 66
pro vyhledávání: '"T. Rossmanith"'
Autor:
Andrea Rubbert-Roth, Hans-Peter Tony, Harald Burkhardt, Martin Aringer, Klaus Krueger, Ulf Müller-Ladner, T. Rossmanith, Michaela Koehm, Marina Backhaus, Rieke Alten, Eva Herrmann, Annette Lehn, Eugen Feist, Frank Behrens, Siegfried Wassenberg, Herbert Kellner, Gerd R Burmester
Publikováno v:
Rheumatology (Oxford, England)
Objective To investigate the efficacy and safety of rituximab + LEF in patients with RA. Methods In this investigator-initiated, randomized, double-blind, placebo-controlled phase 3 trial, patients with an inadequate response to LEF who had failed on
Autor:
Miriam Wolters, Martin Zunftmeister, T. Rossmanith, Gerd Geisslinger, Carmen Walter, Bruno G. Oertel, Jörn Lötsch, Nerea Ferreirós, Sebastian Zinn
Publikováno v:
Basic & Clinical Pharmacology & Toxicology. 126:318-331
Persistent and, in particular, neuropathic pain is a major healthcare problem with still insufficient pharmacological treatment options. This triggered research activities aimed at finding analgesics with a novel mechanism of action. Results of these
Autor:
M. Köhm, T. Rossmanith, A. C. Foldenauer, H. Kellner, U. Kiltz, J. Rech, G. R. Burmester, D. M. Kofler, J. Brandt-Juergens, C. Jonetzko, H. Burkhardt, F. Behrens
Publikováno v:
Annals of the Rheumatic Diseases. 81:850.2-851
BackgroundThe use of bDMARDs treatments in patients with psoriatic arthritis (PsA) usually requires treatment failure or intolerance of csDMARD/MTX before initiation. The value of MTX in combination with bDMARDs is still unclear. We designed an inves
Autor:
M. Köhm, S. Ohrndorf, X. Baraliakos, K. Hallmann, S. Kempinski, A. C. Foldenauer, T. Rossmanith, U. Henkemeier, F. Behrens
Publikováno v:
Annals of the Rheumatic Diseases. 81:874.1-874
BackgroundPsoriasis (PsO) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to PsO; up to 40% of PsO patients develop PsA. The transition from PsO to PsA includes different stages
Autor:
T. Rossmanith, Mukul Ashtikar, Matthias G. Wacker, Gerd Geisslinger, Lisa Nothnagel, Michael J. Parnham, Fabian Jung, Manuela Thurn
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 134:144-152
Since many drugs in the therapy scheme of multiple sclerosis (MS) are applied parenterally with significant side effects, oral treatment is the most accepted therapy option for chronic diseases like MS. The drug candidate TMP-001, which has disease-m
Autor:
Karola Mergenthal, Frank Behrens, Juliana J. Petersen, T. Rossmanith, U. Henkemeier, Harald Burkhardt, Michaela Koehm
Publikováno v:
Oral Presentations.
Background Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease affecting approx. 1% of the adult population of Northern Europe. Strategies for its early detection and diagnosis are of high importance as prompt treatment improves clinica
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
T. Rossmanith, Marina Backhaus, M. Köhm, Harald Burkhardt, G.-R. Burmester, B. Köhler, Sarah Ohrndorf, Siegfried Wassenberg, Frank Behrens
Publikováno v:
Annals of the Rheumatic Diseases. 79:1845.1-1845
Background:Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the skin manifestation appears usually years before PsA-related symptoms emerge. Up to 3
Autor:
Juliana J. Petersen, Karola Mergenthal, T. Oberwahrenbrock, Frank Behrens, Harald Burkhardt, S. Dauth, M. Köhm, T. Rossmanith, U. Henkemeier
Publikováno v:
Annals of the Rheumatic Diseases. 79:946.1-946
Background:Rheumatoid Arthritis (RA) is a chronic inflammatory joint disease. Strategies for its early detection and diagnosis are of high importance as prompt treatment improves clinical and structural outcome. Autoantibodies against cyclic citrulli